SIRIC MONTPELLIER CANCER
Site de Recherche Intégrée sur le Cancer

Master
Biologie-Santé
Montpellier

UNIVERSITÉ DE MONTPELLIER

Fiche proposition de stage - *Internship offers 2025-26*

Offre pour / Offer for (you can make offers for both level, if the subjects are different, please use a new form)

○ **Master 2 (from end January)**

● **Master 1 (from mid January)**

Intitulé du stage *Title*	Harnessing the epitranscriptome to identify new players involved in chemoresistance in ovarian cancer.
Laboratoire d'accueil *Host laboratory*	Institut de Recherche en Cancérologie de Montpellier (IRCM), INSERM U1194, Team " "Epitranscriptomics and Cancer Adaptation"
Nom du responsable *Name of the PI*	Alexandre David
Nom d'encadrant *Supervisor*	Stanislas Quesada
Description (3 phrases) *Description (3 sentences)*	High-grade serous ovarian carcinomas (HGSOC) are the most lethal gynecological malignancies. Due to the absence of symptoms in early stages, 70% of cases are diagnosed at an advanced FIGO stage III/IV. For these advanced stages, there are currently no predictive markers for neoadjuvant chemotherapy effectiveness, as the known indicators of response (e.g., KELIM, CRS) are by definition only available after treatment. As such, we sought to characterize this specific population through epitranscriptomic analysis. Indeed, over the past three years, chemical modifications of RNA have emerged as a new epigenetic layer involved in all stages of gene expression regulation and controlling key biological processes. This Master residency will rely on two aspects: 1/ Biomarker discovery through cutting edge technology for predictive purpose 2/ functional analysis of candidate genes involved in épitranscriptome metabolism, as a new approach to decipher new drivers of chemoresistance.

Durée prevue (2 à 6 mois) Duration (2 to 6 months)	6 months
E-mail	Stanislas.quesada@icm.unicancer.fr Alexandre.david@inserm.fr